AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedEA
Eventide Asset Management
Activity from announced rounds
All recorded activity
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $380M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in all activityLeo Cancer Care
Develops cancer-care systems for treating patients in an upright position.
$65MSeries D
Role not disclosed